316 results on '"Hanauer, S. B."'
Search Results
2. P734 Super-responders in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab maintenance therapy: A post hoc analysis of the LIBERTY-CD study
3. P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials
4. P1009 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
5. P623 Network meta-analysis to evaluate the comparative efficacy of advanced therapies as first line for maintenance treatment of adult patients with moderate-to-severe Crohn’s disease
6. P874 Impact of immunogenicity on clinical outcomes in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study
7. P902 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: 2 years results of the LIBERTY-CD study
8. P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study
9. P983 Treatment of patients with moderate-to-severe Crohn’s disease with subcutaneous infliximab leads to an endoscopic response across all segments of the colon and terminal ileum: A post hoc analysis of the LIBERTY-CD study
10. P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study
11. Ozanimod as induction and maintenance therapy for ulcerative colitis
12. Long‐term safety of adalimumab in clinical trials in adult patients with Crohnʼs disease or ulcerative colitis
13. Induction of remission in ulcerative colitis
14. Potential human models of IBD
15. DOP81 Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn’s Disease in the SERENE studies
16. P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s Disease and Ulcerative Colitis
17. P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study
18. OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study
19. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohnʼs disease
20. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohnʼs disease
21. State-of-the-Art Lecture: The future of biologic therapy in Asia
22. Commentary: pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis
23. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohnʼs disease
24. Evaluation of a daily practice composite score for the assessment of Crohnʼs disease: the treatment impact of certolizumab pegol
25. Randomised clinical trial: certolizumab pegol for fistulas in Crohnʼs disease – subgroup results from a placebo-controlled study
26. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease
27. Review article: evolving concepts in treatment and disease modification in ulcerative colitis
28. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
29. European evidence-based consensus on the diagnosis and management of Crohn’s disease
30. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis
31. New lessons: classic treatments, expanding options in ulcerative colitis
32. Pilot Study On Safety And Effectiveness Of Selective Granulocyte/Monocyte Apheresis In Patients With Inflammatory Bowel Disease: SP25
33. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine
34. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohnʼs disease
35. the long-term management of ulcerative colitis
36. aminosalicylates in inflammatory bowel disease
37. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers1
38. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial
39. Systematic Review: The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis
40. New steroids for IBD: progress report
41. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies
42. Efficacy of parenteral methotrexate in refractory Crohn’s disease
43. Review article: safety of infliximab in clinical trials
44. Repeated infusions of anti-TNF-alpha chimeric antibody (cA2) maintain remission in refractory Crohn's disease 39.05
45. Safety, tolerance and activity of multiple doses of subcutaneous recombinant human interleukin-10 (rHuIL-10) in patients with mild to moderate active Crohn's disease 11.02
46. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial
47. Review article: the medical management of Crohn's disease
48. P343 Efficacy of ustekinumab in Crohn’s disease at maintenance Week 56: IM-UNITI study
49. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
50. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.